What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Clinical Trial Safety Monitoring: How Participant Safety Is Protected

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Clinical trials operate within a multi-layered safety framework involving independent oversight boards, mandatory adverse event reporting, predefined stopping rules, and regulatory oversight from the FDA and international equivalents. Understanding how these protections work can help you make a more informed decision about trial participation.

Institutional Review Boards (IRBs)

Before a trial can begin, an Institutional Review Board — an independent committee of scientists, physicians, ethicists, and community members — must review and approve the protocol. IRBs evaluate whether the trial's risks are reasonable relative to anticipated benefits, whether informed consent procedures are adequate, and whether participant selection is equitable.

IRBs continue to review trials annually and can require protocol modifications or suspend a trial if new safety concerns arise. In the US, all research involving human subjects must have IRB oversight under federal law (45 CFR 46, the "Common Rule").

Data Safety Monitoring Boards (DSMBs)

For Phase 2 and Phase 3 trials, sponsors typically convene a Data Safety Monitoring Board (DSMB) — also called a Data Monitoring Committee (DMC). This independent group of experts has access to unblinded trial data throughout the study, while the sponsor and investigators remain blinded.

DSMBs review accumulating safety data at pre-specified intervals and have authority to recommend:

Early stopping for safety: If unacceptable harm is observed in the treatment arm
Early stopping for efficacy: If the treatment is so clearly beneficial that continuing would be unethical (this is considered a positive outcome)
Continuation with protocol modifications: Dose reduction, enhanced monitoring requirements
Stopping for futility: If the treatment shows no likelihood of benefit

Adverse Event Reporting

All adverse events (AEs) experienced by participants must be recorded and assessed. Serious adverse events (SAEs) — defined as death, life-threatening events, hospitalization, persistent disability, or congenital anomaly — must be reported to the FDA within 7–15 days depending on severity.

Unexpected serious adverse reactions (USARs) — SAEs that were not anticipated based on prior data — trigger immediate review and may result in temporary trial suspension. All sites running the same trial globally are notified of significant safety findings.

FDA and Regulatory Oversight

The FDA maintains ongoing oversight of all IND-stage trials. FDA inspectors conduct site audits to verify that protocols are being followed, adverse events are reported correctly, and informed consent procedures are proper. Non-compliance can result in clinical holds (trial suspension) or disqualification of site data.

Internationally, equivalent oversight is provided by the EMA (European Medicines Agency), MHRA (UK), Health Canada, and other national regulators. International Conference on Harmonisation (ICH) guidelines create a common framework for trial conduct across jurisdictions.

Your Rights if You Experience Harm

If you experience an injury that is directly caused by participation in a clinical trial, you have the right to receive medical treatment for that injury. Whether the sponsor covers the cost of that treatment should be specified in your informed consent form — read this section carefully before enrolling.

Compensation for trial-related injury (beyond medical costs) varies by country and sponsor. US law does not require sponsors to compensate for trial-related injuries beyond medical care, though many do. EU Clinical Trials Regulation 536/2014 requires member states to ensure compensation mechanisms exist.

Questions to Ask the Study Team About Safety

What are the most common side effects seen in prior studies of this drug?
Does this trial have a DSMB, and how often does it review safety data?
Who do I call if I experience a symptom between visits?
Will my treatment costs be covered if I experience a trial-related injury?
Under what circumstances would the trial be stopped?